Sarepta Therapeutics (NASDAQ:SRPT) Posts Earnings Results, Beats Estimates By $0.06 EPS

by · The Markets Daily

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.06, FiscalAI reports. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $381.35 million for the quarter, compared to analysts’ expectations of $352.20 million. During the same period in the prior year, the firm earned ($0.13) earnings per share. The company’s quarterly revenue was down 4.5% compared to the same quarter last year.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

  • Sarepta raised the low end of its 2026 net product revenue guidance by $50 million to $1.25 billion–$1.3 billion, citing strong PMO sales and stabilization in ELEVIDYS. Q3 product revenue was $324 million, down 13% year over year; ELEVIDYS contributed $83 million and the PMO franchise $240 million.
  • ELEVIDYS enrollment-form activity was in line with Q2, which management described as a new baseline; the company expects Q4 ELEVIDYS revenue to be roughly in line with Q3. Executives said long-term data and results in patients ages 8–12 are supporting physician and family discussions, but offered no timing for renewed growth.
  • Sarepta reported $23 million in Q3 non-GAAP operating profit and nearly $1 billion in cash and investments; management said its base business generated nearly $300 million of cash year to date after adjusting for Arrowhead collaboration payments. The company also narrowed its full-year non-GAAP R&D and SG&A expense guidance to $800 million–$825 million.
  • Q3 product-revenue gross margin was 59%, including a $52 million take-or-pay charge for unmanufactured ELEVIDYS inventory that reduced the quarter’s margin by about 19 percentage points. Sarepta also said it expects competition for its exon 51 therapy in early 2027, though it does not expect widespread switching of stable patients initially.
  • Data from the DM1 and FSHD multiple-ascending-dose studies are expected in the coming weeks and are intended to guide dose selection and pivotal-trial plans; those programs have not yet demonstrated clinical benefit in these studies. Sarepta will not resume the ENVISION trial, citing practical barriers, and is relying on ENDEAVOR Cohort 8 data to inform discussions with the FDA about ELEVIDYS in non-ambulatory patients.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $17.82 on Friday. The stock has a market capitalization of $1.88 billion, a P/E ratio of -13.01, a P/E/G ratio of 0.33 and a beta of 0.45. Sarepta Therapeutics has a 1 year low of $14.68 and a 1 year high of $24.68. The company’s fifty day moving average is $19.13 and its two-hundred day moving average is $18.64. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SRPT. William Blair raised Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Finally, JPMorgan Chase & Co. decreased their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have issued a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Reduce” and a consensus target price of $23.40.

View Our Latest Stock Report on Sarepta Therapeutics

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

  • Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
  • Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
  • Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
  • Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.

Featured Articles